Drug
Vorolanib clinical trials
Also written EYP-1901.
- studies test it
- 29
- open now
- 5
- in phase 3
- 6
- first study started
- 2013
Keep track of what changes. Save the vorolanib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
29 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 13
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 7
AnewPharma (13) · EyePoint Pharmaceuticals, Inc. (8) · Dong Wen (1) · Vanderbilt-Ingram Cancer Center (1) · Peking University Cancer Hospital & Institute (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Hao Zeng (1) · Betta Pharmaceuticals Co., Ltd. (1)
Often tested with
Tested in the same studies.
Toripalimab (4) · Everolimus (2) · Cadonilimab (2) · Nivolumab (1) · Sintilimab (1) · Atezolizumab (1) · X-82 (1) · Paclitaxel (1)
Studies
Open first, then newest update. How each study uses vorolanib is read from its arms, and is right about nine times in ten.
Testing it · 29
- Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic ImpairmentRecruitingPhase 1Betta Pharmaceuticals Co., Ltd.NCT07809802Written as vorolanib
- A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKINot yet recruitingPhase 3Peking University Cancer Hospital & InstituteNCT07165418Written as Vorolanib Tablets+Everolimus
- Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC PatientsNot yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06577961Written as Vorolanib
- Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination TherapyNot yet recruitingPhase 2Hao ZengNCT06523049Written as Vorolanib Tablets
- A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung CancerRecruitingPhase 2Henan Cancer HospitalNCT06406673Written as Cadonilimab+vorolanib
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEActive, not recruitingPhase 3EyePoint Pharmaceuticals, Inc.NCT07449923Written as EYP-1901
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEActive, not recruitingPhase 3EyePoint Pharmaceuticals, Inc.NCT07449936Written as EYP-1901
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Active, not recruitingPhase 3EyePoint Pharmaceuticals, Inc.NCT06683742Written as EYP-1901
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56Active, not recruitingPhase 3EyePoint Pharmaceuticals, Inc.NCT06668064Written as EYP-1901
- Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerTerminatedPhase 2Washington University School of MedicineNCT04373369Written as Vorolanib
- Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)CompletedPhase 2EyePoint Pharmaceuticals, Inc.NCT05381948Written as EYP-1901
- Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)CompletedPhase 2EyePoint Pharmaceuticals, Inc.NCT05383209Written as EYP-1901
- Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell CarcinomaActive, not recruitingPhase 2Dong WenNCT07047001Written as Vorolanib Tablets
- Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)CompletedPhase 2EyePoint Pharmaceuticals, Inc.NCT06099184Written as EYP-1901
- Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic TumorsCompletedPhase 1/2Vanderbilt-Ingram Cancer CenterNCT03583086Written as Vorolanib
- First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)CompletedPhase 1EyePoint Pharmaceuticals, Inc.NCT04747197Written as EYP-1901
- The Absorption, Metabolism and Excretion of [14C]CM082 in HumanCompletedPhase 1AnewPharmaNCT04434326Written as [14]CM082 suspension
- Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid TumorsStatus unknownPhase 1AnewPharmaNCT03792958Written as CM082
- Bioequivalency Study of CM082 Tablet in Healthy VolunteersCompletedPhase 1AnewPharmaNCT04328506Written as CM082 tablet (test product)
- CM082 in Patients With Myopic Choroidal Neovascularization (CNV)SuspendedPhase 1AnewPharmaNCT04222842Written as CM082
See all 29 studies that test vorolanib →
Given in every arm · 1 — vorolanib is usual care beside what is tested
Codes
What other systems call vorolanib · ClinicalTrials.gg INT001380
- MeSH (NLM) C000709220vorolanibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) YP8G3I74ELVOROLANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27294638vorolanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95896VorolanibOne source FDA
- DrugBank DB15247One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000709220 | vorolanib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | YP8G3I74EL | VOROLANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27294638 | vorolanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95896 | Vorolanib | One source FDA |
| DrugBank | DB15247 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.